TCR-T cell therapy for HLA-A*02 positive solid tumors
Part of Cancer clinical trials.
This trial tests a personalized immune-cell treatment made from your own blood to target certain solid tumors. You may be eligible if your tumor has a specific protein pattern and you have tried standard treatments without success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18–70 years old and be able to sign consent and complete study visits and tests
- You have a solid cancer that has not responded to standard treatments
- Your body must have HLA-A*02, and your tumor must show the target protein strongly (2+ or 3+ in enough cells)
- Any side effects from prior cancer treatments must be mostly gone (grade 0–1 or an acceptable level)
- Your blood, liver, kidney, and clotting tests must be good enough for treatment
- A tumor tissue sample must be available for target testing (archived sample or fresh biopsy; bone biopsy not accepted)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immunotherapy using specially engineered immune cells (called TCR-enhanced Vδ2 T cells) to treat blood cancers or solid tumors that haven't responded to standard treatments. The goal is to see if these cells can safely shrink tumors and improve survival.
This trial tests a new type of immune cell therapy (TCR-T) designed to attack cancer cells with a specific KRAS mutation. It may be an option for people with advanced solid tumors who have run out of standard treatments.
This trial tests a personalized treatment that uses your own immune cells, modified to recognize and attack your cancer. It may help people with advanced solid tumors who have not improved with standard treatments.
This study tests a personalized treatment made from your own immune cells (T cells) that are re-engineered to recognize and attack your specific tumor. It is for people with advanced solid tumors that have not responded to other treatments. If you qualify, you will have a blood draw and a tumor sample collected to create your own custom T cell therapy.
This phase 1 trial tests a new way to use your own immune cells to fight advanced solid tumors. The treatment is given directly into the tumor. It is for people who have run out of standard treatment options.
This trial tests a new therapy using your own immune cells, engineered to recognize and attack cancer cells. It is for people with advanced solid tumors who have no other standard treatment options.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.